All In Biotech

Drug Trial Radar · NCT07192614

A Study to Learn How Safe AZD6621 is, How Well it Works, and How it Moves Throughout the Body Over Time, in Adult Male Participants With Metastatic Prostate Cancer

A Phase I/II Open-label, Dose Escalation and Dose Expansion Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of AZD6621, a T Cell-engaging Antibody That Targets STEAP2, CD3, and CD8 in Adult Participants With Metastatic Prostate Cancer

Last checked: Nov 19, 2026Latest source record: Sep 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

52

Planned (sponsor's estimate)

Start

Sep 30, 2025

Primary completion

Mar 29, 2029

Study completion Mar 29, 2029

Sponsor

Lead sponsor
AstraZenecaAstraZeneca (AZN)
Sponsor type
Industry
First posted
Sep 25, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
Male only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is being conducted to learn more about the safety, tolerability, and effectiveness of an experimental treatment for metastatic prostate cancer called AZD6621. The study is split into different modules which will look at AZD6621 delivered by different methods. The study is also further split into 2 parts, Part A which will test different dose levels of AZD6621 to determine which doses are the best in terms of safety and side effects (dose escalation), and Part B will further test at least two AZD6621 doses in a larger group of participants (dose expansion).

Conditions

  • Prostate Cancer

Interventions

  • AZD6621Drug

    A T Cell-engaging Antibody that targets STEAP2, CD3, and CD8

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of participants with adverse events (AE), adverse events of special interest (AESI), and serious adverse events (SAE)Time frame: From time of Informed Consent to 90 days post last dose of study intervention (up to 3 years)
  2. Number of participants with dose-limiting toxicity (DLT), as defined in the protocol (Part A only)Time frame: From first study dose to 21 to 28 days post first dose
  3. Preliminary anti-tumour activity of AZD6621 (PSA Response Rate) (Part B only)Time frame: Up to 3 years

Locations

26 sites in 9 countries. Site status is shown where the registry gives one.

  • Research Site

    Orlando, Florida · Recruiting

  • Research Site

    Tampa, Florida · Recruiting

  • Research Site

    Boston, Massachusetts · Withdrawn

  • Research Site

    Grand Rapids, Michigan · Recruiting

  • Research Site

    Commack, New York · Recruiting

  • Research Site

    Providence, Rhode Island · Recruiting

  • Research Site

    Brussels, Belgium · Not yet recruiting

  • Research Site

    Ghent, Belgium · Not yet recruiting

  • Research Site

    Québec, Canada · Recruiting

  • Research Site

    Toronto, Ontario, Canada · Not yet recruiting

  • Research Site

    Beijing, China · Recruiting

  • Research Site

    Chengdu, China · Suspended

  • Research Site

    Guangzhou, China · Suspended

  • Research Site

    Nanjing, China · Not yet recruiting

  • Research Site

    Chūōku, Japan · Recruiting

  • Research Site

    Hirakata-shi, Japan · Recruiting

  • Research Site

    Kashiwa, Japan · Recruiting

  • Research Site

    Amsterdam, Netherlands · Not yet recruiting

  • Research Site

    Maastricht, Netherlands · Not yet recruiting

  • Research Site

    Seoul, South Korea · Recruiting

  • Research Site

    Seoul, South Korea · Recruiting

  • Research Site

    Barcelona, Spain · Not yet recruiting

  • Research Site

    L'Hospitalet de Llobregat, Spain · Not yet recruiting

  • Research Site

    Madrid, Spain · Recruiting

  • Research Site

    Cambridge, United Kingdom · Recruiting

  • Research Site

    Manchester, United Kingdom · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.